Similar Search Results

Liberalizing the opening of new pharmacies and hospitalizations

Cintolesi, Andrea; Riganti, Andrea - 2022

Persistent link: https://www.econbiz.de/10013464684

TRIPS flexibilities and access to medicines : an evaluation of barriers to employing compulsory licenses for patented pharmaceuticals at the WTO

Wong, Anna S. Y.; Cole, Clarke B.; Kohler, Jillian Clare - 2022

without the patent owner's authorization by issuing a compulsory license (CL). In the pharmaceuticals space, governments have … before patent expiry, increasing the supply and reducing the price of patented pharmaceuticals domestically. This paper … evaluates the three primary barriers to employing compulsory licenses for pharmaceuticals underscored by members during TRIPS …

Persistent link: https://www.econbiz.de/10013469578

Compulsory License, a Long Debate on TRIPS Agreement Interpretation : Discovering the Truth of Thailand’s Imposition on Pharmaceutical Patents

Suwan-in, Nattapong - 2014

This article investigates interpretative difficulty in compulsory licensing dispute by taking the Thailand case of imposition on medicines during 2007 to 2008 as a model for our study and consideration. The country’s actions are arguably unique, aggressive and direct as per TRIPS wording which...

Persistent link: https://www.econbiz.de/10014167418

Compulsory licensing : India's maiden experience

Gautam, Savita; Dasgupta, Meghna - 2013

Under the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) all parties to the agreement are allowed flexibility in issuing licenses for manufacturing pharmaceutical drugs, in line with their public policy objectives. The licenses may be issued under certain conditions,...

Persistent link: https://www.econbiz.de/10010211996

The More Things Change : Improvement Patents, Drug Modifications, and the FDA

Karshtedt, Dmitry - 2021

Pharmaceutical companies often replace prescription drugs that are already on the market with modified versions that have the same active pharmaceutical ingredient. On the surface, such activity seems benign and perhaps even salutary. Nonetheless, antitrust litigation has revealed that firms...

Persistent link: https://www.econbiz.de/10013224253

The Invention of an Investment Incentive for Pharmaceutical Innovation

Basheer, Shamnad - 2015

Pharmaceutical drugs are often hailed as the poster child for the proposition that patents foster accelerated rates of innovation. This sentiment stems, in large part, from the belief that pharmaceutical research and development (R&D) entails significant costs and resources. I argue that if the...

Persistent link: https://www.econbiz.de/10014161723

Alternative Incentives for Pharmaceutical Innovation

Basheer, Shamnad - 2015

The current patent system is muddied with manifest muck. Even those that revere its relevance for R&D intensive sectors such as pharmaceutical drugs, admit of its various failings, particularly when it comes to incentivising research into neglected diseases. A number of alternative innovation...

Persistent link: https://www.econbiz.de/10014132514

Regulated Arbitrage and Parallel Importation of Trademarked Pharmaceuticals in the European Union

Ryan PhD, Patrick Spaulding - 2004

The pharmaceutical market in Europe, in its present circumstances, is not organized according to the principles of free trade to which other products are subjected. Under this situation, the owners of trade-marks have tried to develop price and market strategies consistent with their interests...

Persistent link: https://www.econbiz.de/10014068137

Gender Inequality in Pharmaceutical Patent Law

Tu, S. Sean; Hardesty, Tess - 2023

technical fields (the “pipeline” theory), this study rebuts the pipeline theory. Specifically, the study shows that women law …

Persistent link: https://www.econbiz.de/10014359052

Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008

Varol, Nebibe - 2014

Generic competition in the pharmaceutical market is an effective cost-containment mechanism that improves static efficiency and stimulates pharmaceutical innovation. There is no prior study that has empirically analysed the relative delays in adoption of generic competition. This paper aims to...

Persistent link: https://www.econbiz.de/10013068052